Journal article
ONE-YEAR RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION INVESTIGATION (TIMI) PHASE II TRIAL
DO WILLIAMS, E BRAUNWALD, G KNATTERUD, J BABB, J BRESNAHAN, MA GREENBERG, A RAIZNER, A WASSERMAN, T ROBERTSON, R ROSS, B THOMPSON, WR BELL, L SCHERLIS, HT DODGE, BG BROWN, JW KENNEDY, FH SHEEHAN, B BISSON, E BOLSON, B ZARET Show all
CIRCULATION | LIPPINCOTT WILLIAMS & WILKINS | Published : 1992
Abstract
BACKGROUND: The Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial randomized 3,339 patients to either an invasive (INV, n = 1,681) or a conservative (CON, n = 1,658) strategy after intravenous recombinant tissue-type plasminogen activator (rt-PA) for acute myocardial infarction. METHODS AND RESULTS: The patients assigned to the INV strategy routinely underwent cardiac catheterization, and when anatomically appropriate, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass grafting 18-48 hours after infarction. CON patients had these procedures only in response to the occurrence of spontaneous or provoked ischemia. One-year follow-up data are available in 3..
View full abstract